Stockscreener 앱 받기
3.67
6.14%
-0.24
시간 외 거래:
3.59
-0.08
-2.18%
전일 마감가:
$3.91
열려 있는:
$3.87
하루 거래량:
188.85K
Relative Volume:
1.26
시가총액:
$36.52M
수익:
$20.34M
순이익/손실:
$-24.52M
주가수익비율:
-1.0263
EPS:
-3.5761
순현금흐름:
$-5.92M
1주 성능:
-10.05%
1개월 성능:
-10.71%
6개월 성능:
-56.31%
1년 성능:
-42.66%
1일 변동 폭
$3.535
$3.88
1주일 범위
$3.535
$4.15
52주 변동 폭
$3.53
$9.12
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
3.67 | 36.52M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-22 | 개시 | Guggenheim | Buy |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-11 | 업그레이드 | Needham | Hold → Buy |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-10 | 개시 | ROTH Capital | Buy |
| 2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
| 2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-20 | 개시 | H.C. Wainwright | Buy |
| 2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2016-08-17 | 개시 | Guggenheim | Buy |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 개시 | Brean Capital | Buy |
| 2015-12-29 | 개시 | WBB Securities | Speculative Buy |
| 2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-06-10 | 개시 | Needham | Buy |
| 2014-05-29 | 개시 | Canaccord Genuity | Buy |
| 2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Nigeria
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com
SCYNEXIS (SCYX) Completes Phase 1 Trial for SCY-770 Targeting AD - GuruFocus
SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Canada
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative
SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative
An experimental kidney disease drug was well tolerated in 25 healthy adults - Stock Titan
SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions - Simply Wall Street
Stock splits calendar for: - Yahoo Finance UK
Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 - AllSci
Scynexis wins BARDA contract worth up to $214 million for antifungal SCY-247 - The Pharma Letter
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline - TipRanks
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Scynexis stock surges on $214M BARDA contract for SCY-247 - Yahoo Finance
Scynexis stock surges on $214M BARDA contract for SCY-247 - Investing.com
SCYX Stock Draws Trader Focus As New CFO And ADPKD Pivot Take Shape - timothysykes.com
SCYX Stock Draws Traders As Leadership And Kidney Pivot Advance - StocksToTrade
SCYNEXIS Wins BARDA Contract Worth Up to $214 Million for SCY-247 - citybiz
SCYNEXIS secures BARDA contract for antifungal development - Investing.com
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract - Yahoo Finance
Why is Scynexis stock surging today? By Investing.com - Investing.com South Africa
Why is Scynexis stock surging today? By Investing.com - Investing.com Canada
Why is Scynexis stock surging today? - Investing.com
SCYNEXIS secures BARDA contract for antifungal development By Investing.com - Investing.com India
A U.S. health agency could provide up to about $214 million to develop an antifungal treatment if all options are exercised. - Stock Titan
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch - TradingView
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - manilatimes.net
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - marketscreener.com
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - Stock Titan
Press Release: SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to Its Board of Directors - Moomoo
SCYXPhase II ADPKD Catalyst Will Define Long-Term Potential For This Orphan Kidney Therapy - Simply Wall Street
SCYNEXIS (Nasdaq:SCYX)Stock Analysis - Simply Wall Street
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com Nigeria
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com India
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.08%
1.49%
자본화:
|
볼륨(24시간):